Intas Pharmaceuticals has further reinforced its leadership cadre with the appointment of Vijay Dabade as Associate Vice President – Quality Control, marking a strategic step in the company’s ongoing efforts to enhance its global quality systems and regulatory alignment. Dabade brings over two decades of experience in pharmaceutical quality management, spanning core functions such as laboratory operations, analytical excellence, GMP compliance, and regulatory audits across multiple geographies.

Throughout his career, Dabade has led quality transformation initiatives for reputed pharmaceutical organisations, strengthening their readiness for stringent regulatory inspections, including USFDA, MHRA, EMA, and WHO. His expertise in implementing harmonised quality frameworks and driving continuous improvement will play a critical role in advancing Intas’ quality priorities across its expanding operations.

Intas Pharma: A Global Powerhouse in Formulations, Biosimilars & High-Value Products

Headquartered in Ahmedabad, Intas Pharma is among India’s leading integrated pharmaceutical companies with a strong focus on development, manufacturing, and commercialisation of high-quality, affordable medicines. The company operates globally through its well-established subsidiary network under the Accord Healthcare brand, enabling it to cater to regulated as well as emerging markets.

Intas’ footprint now spans 85+ countries, supported by 20+ state-of-the-art manufacturing facilities accredited by leading global regulators. It is recognised for its robust capabilities across oral solids, injectables, oncology formulations, and advanced biologics. The company has also emerged as a major player in the global biosimilars market, with several products already commercialised in Europe and additional innovations in late-stage development.

In recent years, Intas has significantly accelerated its investments in high-entry-barrier technologies, novel drug delivery systems, and New Chemical Entities (NCEs)—reflecting its commitment to a more innovation-driven pipeline. The company’s strong emphasis on quality, patient safety, and regulatory excellence forms the backbone of its global growth strategy.

Also read: Eli Lilly Becomes First Healthcare Company Globally to Cross $1 Trillion Market Cap, Driven by Explosive GLP-1 Growth

Strengthening Quality to Support Next-Stage Expansion

The appointment of Vijay Dabade is aligned with Intas Pharma’s long-term vision of building world-class quality systems as it scales up complex manufacturing, global filings, and biologics-led growth. Dabade’s leadership is expected to reinforce Intas’ quality culture and support its mission to deliver reliable, compliant, and globally competitive pharmaceutical products.

His addition signals Intas’ continued focus on operational excellence, scientific innovation, and quality-driven expansion—key pillars that will fuel the company’s next phase of global growth.

Like 1

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!